LexaGene Holdings Inc. (TSX-V:LXG, OTCQB:LXXGF) said it has been selected as a Best in Show Spotlight company at the Petcare Innovation Summit to be held in Boston, Massachussetts in early December.
“It is an honor to have LexaGene selected amongst the many applicants. I’m pleased the selection committee recognized how innovative and revolutionary the MiQLab System is for the veterinary industry,” said LexaGene CEO Dr Jack Regan in a statement.
“The MiQLab allows for in-hospital evidence-based decision making so antimicrobials are only prescribed when necessary and are appropriately selected. I’m excited to have LexaGene lead the way to promote a new wave of diagnostic testing for the veterinary market. This speaking engagement gives the Company the opportunity to speak directly to industry leaders as well as investors focused on funding innovative life sciences companies.”
READ: LexaGene completes analytical studies for FDA EUA application for coronavirus (COVID-19) diagnostics
The company said start-ups and emerging pet care brands are invited to the Petcare Innovation Summit where introductions can accelerate growth, strengthen the investment pipeline, and expose brands to executives who are looking for game-changers within the industry.
According to the Summit organizers:
- More than US$110 billion will be spent in the pet industry in 2021
- More than 65% of all US families own a pet
- During the coronavirus (COVID-19) pandemic, nearly one in three Americans adopted a pet
- Millennials now represent the biggest share of pet owners in the US
Dr Regan added: “The veterinary industry is booming and we’re not seeing any indication of it slowing down. Most veterinarians are overwhelmed by the flood of new pets from pandemic-fueled adoptions and LexaGene’s MiQLab system offers these veterinarians a much more efficient way to diagnose and treat animals – which will minimize the number of return visits due to unresolved infections.”
The 47th Annual Petcare Innovation Summit will be held in Boston on December 7-8, 2021, at the Hilton Back Bay Hotel. To register for the conference, investors can visit the website.
LexaGene’s MiQLab System is designed for in-clinic use and screens for common bacterial infections and antimicrobial resistance factors, returning results in less than 2 hours versus multiple days for laboratory-based results.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham